|
|
| Line 45: |
Line 45: |
| ==Treatment== | | ==Treatment== |
| [[Kidney cancer medical therapy|Medical therapy]] | [[Kidney cancer surgery|Surgical options]] | [[Kidney cancer primary prevention|Primary prevention]] | [[Kidney cancer secondary prevention|Secondary prevention]] | [[Kidney cancer cost-effectiveness of therapy|Financial costs]] | [[Kidney cancer future or investigational therapies|Future therapies]] | | [[Kidney cancer medical therapy|Medical therapy]] | [[Kidney cancer surgery|Surgical options]] | [[Kidney cancer primary prevention|Primary prevention]] | [[Kidney cancer secondary prevention|Secondary prevention]] | [[Kidney cancer cost-effectiveness of therapy|Financial costs]] | [[Kidney cancer future or investigational therapies|Future therapies]] |
|
| |
| ==Treatment==
| |
|
| |
| If the tumor is confined to the kidneys (occurs in about 40% of cases), then RCC can be treated roughly 90% of the time with [[surgery]]. If RCC has spread outside of the kidneys, often into the [[lymph nodes]] or the main vein of the kidney, then it is often treated with [[chemotherapy]] and other treatments.
| |
|
| |
| ===Watchful waiting===
| |
|
| |
| Small renal tumors represent the majority of tumors that are treated today by way of partial [[nephrectomy]]. The average growth of these masses is about 4-5 mm per year, and a significant proportion (up to 40%) of tumors less than 4cm in diameter are benign. More centers of excellence are incorporating needle biopsy to confirm the presence of malignant histology prior to recommending definitive surgical extirpation. In the elderly, patients with co-morbidities and in poor surgical candidates, small renal tumors may be monitored carefully with serial imaging. Most clinicians conservatively follow tumors up to a size threshold between 3-5 cm, beyond which the risk of distant spread (metastases) is about 5%.
| |
|
| |
| ===Surgery===
| |
|
| |
| Surgical removal of all or part of the kidney ([[nephrectomy]]) is recommended. This may include removal of the [[adrenal gland]], retroperitoneal lymph nodes, and possibly tissues involved by direct extension (invasion) of the tumor into the surrounding tissues. In cases where the tumor has spread into the [[renal vein]], [[inferior vena cava]], and possibly the [[right atrium]] (angioinvasion), this portion of the tumor can be surgically removed, as well. In case of metastases surgical resection of the kidney ("cytoreductive nephrectomy") may improve survival<ref>Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004 Mar;171(3):1071-6. PMID 14767273.</ref>, as well as resection of a solitary metastatic lesion.
| |
|
| |
| ===Percutaneous therapies===
| |
|
| |
| [[Percutaneous]], image-guided therapies, usually managed by [[radiologists]], are being offered to patients with localized tumor, but who are not good candidates for a surgical procedure. This sort of procedure involves placing a probe through the skin and into the tumor using real-time imaging of both the probe tip and the tumor by [[computed tomography]], [[ultrasound]], or even [[magnetic resonance imaging]] guidance, and then destroying the tumor with heat ([[radiofrequency ablation]]) or cold ([[cryotherapy]]). These modalities are at a disadvantage compared to traditional surgery in that pathologic confirmation of complete tumor destruction is not possible.
| |
|
| |
| ===Radiation therapy===
| |
|
| |
| [[Radiation therapy]] is not commonly used for treatment of renal cell carcinoma because it is usually not successful. Radiation therapy may be used to palliate the symptoms of skeletal metastases.
| |
|
| |
| ===Medications===
| |
|
| |
| RCC "elicits an immune response, which occasionally results in dramatic spontaneous remissions." This has encouraged a strategy of using immunomodulating therapies, such as cancer vaccines and [[interleukin-2]] (IL-2), to reproduce this response. IL-2 has produced "durable remissions" in a small number of patients, but with substantial toxicity. Another strategy is to restore the function of the VHL gene, which is to destroy proteins that promote inappropriate vascularization. [[Bevacizumab]], an antibody to [[VEGF]], has significantly prolonged time to progression, but phase 3 trials have not been published. Sunitinib (Sutent), sorafenib (Nexavar), and temsirolimus, which are small-molecule inhibitors of proteins, have been approved by the U.S. F.D.A.<ref>{{cite journal |author=Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E |title=Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma |journal=N Engl J Med. |volume=358 |issue=22 |pages=2389–96 |year=2008 |month=May |pmid=18509125 |doi=10.1056/NEJMcpc0802449 |url=http://content.nejm.org/cgi/content/full/358/22/2389}}</ref>
| |
|
| |
| [[Sorafenib]] was FDA approved in December 2005 for treatment of advanced renal cell cancer, the first receptor tyrosine [[kinase]] (RTK) inhibitor indicated for this use.
| |
|
| |
| A month later, [[Sunitinib]] was approved as well. Sunitinib—an oral, small-molecule, multi-targeted (RTK) inhibitor—and sorafenib both interfere with tumor growth by inhibiting [[angiogenesis]] as well as tumor cell proliferation. Sunitinib appears to offer greater potency against advanced RCC, perhaps because it inhibits more receptors than sorafenib. However, these agents have not been directly compared against one another in a single trial. [http://www.cancer.gov/Templates/drugdictionary.aspx?searchTxt=sunitinib][http://www.cancer.gov/Templates/drugdictionary.aspx?searchTxt=sorafenib]
| |
|
| |
| Recently the first Phase III study comparing an RTKI with cytokine therapy was published in the ''[[New England Journal of Medicine]]''. This study showed that [[Sunitinib]] offered superior efficacy compared with [[interferon-α]]. Progression-free survival (primary endpoint) was more than doubled. The benefit for sunitinib was significant across all major patient subgroups, including those with a poor prognosis at baseline. 28% of sunitinib patients had significant tumor shrinkage compared with only 5% of patients who received interferon-α. Although overall survival data are not yet mature, there is a clear trend toward improved survival with sunitinib. Patients receiving sunitinib also reported a significantly better quality of life than those treated with IFNa. <ref name=motzer>{{cite journal | author = Motzer RJ ''et al.'' | title = Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | journal = [[New England Journal of Medicine|N Engl J Med]] | volume = 356 | issue = 2 | pages = 115–124 | year = 2007 | pmid = 17215529 | doi = 10.1056/NEJMoa065044}} </ref> Based on these results, lead investigator Dr. Robert Motzer announced at ASCO 2006 that “Sunitinib is the new reference standard for the first-line treatment of mRCC.” <ref name=motzer2>{{cite conference
| |
| |author=Motzer RJ ''et al.'' | title=Phase 3 Randomized Trial of Sunitinib malate (SU11248) versus Interferon-alfa as First-line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma |booktitle=ASCO 2006 |url=http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&index=y&abstractID=30512}} </ref>
| |
|
| |
| Temsirolimus (CCI-779) is an inhibitor of mTOR kinase (mamallian target of rapamycin) that was shown to prolong overall survival vs. interferon-α in patients with previously untreated metastatic renal cell carcinoma with three or more poor prognostic features. The results of this Phase III randomized study were presented at the 2006 annual meeting of the American Society of Clinical Oncology (www.ASCO.org).
| |
|
| |
| ===Chemotherapy===
| |
|
| |
| [[Chemotherapy]] may be used in some cases, but cure is unlikely unless all the cancer can be removed with surgery. The use of Tyrosine Kinase (TK) inhibitors, such as [[Sunitinib]] and [[Sorafenib]], and [[Temsirolimus]] are described in a different section.
| |
|
| |
| ===Vaccine===
| |
|
| |
| In November 2006, it was announced that a [[vaccine]] had been developed and tested with very promising results.(See [http://www.dailymail.co.uk/pages/live/articles/news/news.html?in_article_id=416006&in_page_id=1770]) The new vaccine, called [[TroVax]], works by harnessing the patient's own immune system to fight the disease. Oxford BioMedica[http://www.oxfordbiomedica.co.uk/]. Further vaccine trials are underway.
| |
|
| |
| ===Cryoablation===
| |
|
| |
| This involves destroying the kidney tumor without surgery, by freezing the tumor. The process can remove 95% of tumors in one treatment and can be tolerated by patients who are not good candidates for surgery (older or weak patients). <ref> <http://www.yourcancertoday.com/news/drnakada.html" title=" Dr. Nakada, on Your Cancer Today</ref>.
| |
|
| |
| The outcome varies depending on the size of the tumor, whether it is confined to the kidney or not, and the presence or absence of metastatic spread. The Fuhrman grading, which measures the aggressiveness of the tumor, may also affect survival, though the data is not as strong to support this.
| |
|
| |
| The [[five year survival rate]] is around 90-95% for tumors less than 4 cm. For larger tumors confined to the kidney without venous invasion, survival is still relatively good at 80-85%. For tumors that extend through the renal capsule and out of the local fascial investments, the survivability reduces to near 60%. If it has metastasized to the lymph nodes, the 5-year survival is around 5 % to 15 %. If it has spread metastatically to other organs, the 5-year survival rate is less than 5 %.
| |
|
| |
| For those that have tumor recurrence after surgery, the prognosis is generally poor. Renal cell carcinoma does not generally respond to chemotherapy or radiation. Immunotherapy, which attempts to induce the body to attack the remaining cancer cells, has shown promise. Recent trials are testing newer agents, though the current complete remission rate with these approaches are still low, around 12-20% in most series.
| |
|
| |
|
| ==Prognosis== | | ==Prognosis== |
For patient information click here
Template:DiseaseDisorder infobox
Steven C. Campbell, M.D., Ph.D.
Contributors: C. Michael Gibson, M.S., M.D., Cafer Zorkun M.D., PhD.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic:
There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Synonyms and Key Words: RCC, renal cell, renal cell CA, renal cell carcinoma, kidney cancer, kidney carcinoma, kidney CA, Grawitz tumor, hypernephroma
Diagnosis
History and Symptoms | Physical Examination | Staging | Laboratory tests | Electrocardiogram | X Rays | CT | MRI Echocardiography or Ultrasound | Other images | Alternative diagnostics
Treatment
Medical therapy | Surgical options | Primary prevention | Secondary prevention | Financial costs | Future therapies
Prognosis
The outcome varies depending on the size of the tumor, whether it is confined to the kidney or not, and the presence or absence of metastatic spread. The Furhman grading, which measures the aggressiveness of the tumor, may also affect survival, though the data is not as strong to support this.
The five year survival rate is around 90-95% for tumors less than 4 cm. For larger tumors confined to the kidney without venous invasion, survival is still relatively good at 80-85%. For tumors that extend through the renal capsule and out of the local fascial investments, the survivability reduces to near 60%. If it has metastasized to the lymph nodes, the 5-year survival is around 5 % to 15 %. If it has spread metastatically to other organs, the 5-year survival rate is less than 5 %.
For those that have tumor recurrence after surgery, the prognosis is generally poor. Renal cell carcinoma does not generally respond to chemotherapy or radiation. Immunotherapy, which attempts to induce the body to attack the remaining cancer cells, has shown promise. Recent trials are testing newer agents, though the current complete remission rate with these approaches are still low, around 12-20% in most series.
See also
External links
References
Template:Tumors
Template:Nephrology
Template:Tumor morphology
Template:SIB
bs:Rak bubrega
de:Nierenkrebs
hr:Rak bubrega
it:Cancro del rene
fi:Munuaissyöpä
sv:Njurcancer
Template:WikiDoc Sources